| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
2 companies
Ligand Pharmaceuticals Inc is 10% Owner at VKTX, with reported holdings spanning 2 companies.
Ligand Pharmaceuticals Inc's largest disclosed position is in VKTX as 10% Owner, worth about $151.8M. The VKTX filings lean toward selling, a net 427,369 shares.
Ligand Pharmaceuticals Inc has 7 Form 4 filings on record from May 2015 to December 2025, across 2 companies: Director, 10% Owner at Pelthos Therapeutics (PTHS), 2025; 10% Owner at Viking Therapeutics (VKTX), 2015–2020.
The 13 reported transactions were 3 option or other derivative awards, 3 other transactions, 3 open-market sales and 2 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $6.4M.
The largest open-market sale was 262,881 shares of VKTX at an average $19.15 on September 25, 2018, about $5.0M.